This article was originally published in The Gray Sheet
Executive SummaryAppoints J. Daniel Cole to the newly created position of executive vice president and chief operating officer, effective April 12. Cole comes to Scimed after 10 years at Baxter. Most recently, Cole was president of Baxter's Edwards Critical Care Division.
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.